Research Articles - Retinitis Pigmentosa
Oregon Health & Science University (OHSU) is launching a three-year natural history study for people with X-linked retinoschisis (XLRS). Funded by the Foundation Fighting Blindness and Applied Genetic Technologies Corporation (AGTC), the investigation’s primary goal is to identify outcome measures — such as changes in vision or retinal structure — that could be useful in evaluating the effectiveness of
A highly potent synthetic form of THC, the substance in marijuana that produces a high for users, has shown strong vision-preserving effects in rats with a form of autosomal dominant retinitis pigmentosa (adRP). Rats with adRP that were injected with the synthetic THC known as HU210 had 40 percent more rows of photoreceptors and 70 percent greater retinal sensitivity than untreated rats. The treatment also protected the connections between photoreceptors and other
- ReNeuron, a stem cell development company in the United Kingdom, is planning to file for regulatory approval in late 2013 to launch a clinical trial of a stem cell treatment for people with retinitis pigmentosa. The company announced its plans on June 15, 2012, at the 10th Annual Meeting of the International Society for Stem Cell Research (ISSCR) in Yokohama, Japan.
A grandmother of 10 who was diagnosed with retinitis pigmentosa (RP) 25 years ago is one of the first two people to receive an implant of the Argus® II Retinal Prosthesis System since it became commercially available in the United States. She is hopeful that the device, when activated after she recovers from surgery and receives training, will enable her to travel more and see the movement and activity of her grandchildren.
- A team led by Dr. Stephen Daiger, a researcher from the University of Texas Health Science Center in Houston, used genetic testing to determine that 8.5 percent of people thought to have autosomal dominant retinitis pigmentosa (adRP) actually have X-linked RP (XLRP). The investigators tested individuals from a group of 258 families initially diagnosed with adRP. Results of the Foundation-funded study were
A retinal prosthesis known to many as “the bionic retina” was implanted for the first time commercially in a patient in a hospital in Pisa, Italy, on October 29. Called the Argus II Retinal Prosthesis System, it was surgically implanted by Dr. Stanislao Rizzo, director of the University
- All 12 participants in the gene therapy clinical trial for Leber congenital amaurosis (LCA) at the Children’s Hospital of Philadelphia (CHOP) have been so delighted with the vision restoration from treatment to one eye, they have been anxiously awaiting the go-ahead to have their second eye treated. Thanks to results from a Foundation-funded lab study in large animals, that will likely happen soon.
Drs. Al Maguire, Katherine High, and Jean Bennett, lead investigators on the
A Foundation-funded research team has developed a gene therapy that restored vision in mice which had lost half of their photoreceptors to autosomal recessive retinitis pigmentosa (arRP) caused by mutations in the gene PDE6α. Results of the study, led by Stephen Tsang, M.D., Ph.D., of Columbia University, were published in the journal Human
- The three-year, 90-participant clinical study will be conducted at three sites — the University of Massachusetts Medical School, the University of Utah, and the Retina Foundation of the Southwest — under the auspices of the National Eye Evaluation Research Network. The Foundation Fighting Blindness established the network to launch clinical trials of promising treatments and cures for retinal degenerative diseases. Valproic acid is the first treatment to be evaluated in the network.
Valproic acid appears to work by masking certain protein defects that can cause
- While Second Sight Medical Products is actively moving out its Argus II retinal prosthesis systems to blind patients in the United States and Europe, the developer of the first commercially available bionic retina also has its eye on the future. The company is working on a number of upgrades and enhancements to restore vision in more patients and improve the visual experience for existing users.
In a presentation at the Foundation’s